Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
By J. Wolchok, B. Neyns, G. Linette, S. Négrier, J. Lutzky, L. Thomas, W. Waterfield, D. Schadendorf, M. Smylie, T. Guthrie and 7 more. The Lancet Oncology, 2010
1,146 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/98fddb112f844ebd38e2bf2078a8e3b2fa22018b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “3 mg/kg ipilimumab, whereas these toxicities increased to 30% with a dose of 10 mg/kg [3].”
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “3 mg/kg ipilimumab, whereas these toxicities increased to 30% with a dose of 10 mg/kg [3].”
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Anti-CTLA4 mAbs are associated with elevated AST and ALT levels in 10% of patients or less [20, 21, 54, 69].”
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (2016, result): “This frequency is higher than that observed with the same dose in the pooled analysis involving patients with advanced melanoma.(2-4) The vast majority of immune-related adverse events of grade 2, 3, or 4 resolved within 4 to 8 weeks with the use of established management guidelines.”
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis (2015, methodology): “However, in the subgroup analysis [17, 19, 30], a statistically significant difference was only found between the two doses for all grade gastrointestinal irAEs with a RR of 1.”
- Management of toxicities of immune checkpoint inhibitors. (2016, background): “Higher doses of ipilimumab (ie 10 mg/kg) appear to increase rates of irAEs in melanoma, though we await results from a trial of 3 mg/kg versus 10 mg/kg in the advanced setting to directly compare the two (NCT02279862) [12].”
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017, background): “Of note, approximately 20% of ipilimumabtreated patients with melanoma experienced long-term survival.(17,18,20-26) Results of a phase I/II dose-finding study of ipilimumab in 71 chemotherapy-naive or chemotherapy-pretreated patients with metastatic CRPC (mCRPC) showed antitumor activity in this cli”